Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I Study of Intratumoral CV8102 in Patients With Advanced Melanoma, Squamous Cell Carcinoma of the Skin, Squamous Cell Carcinoma of the Head and Neck, or Adenoid Cystic Carcinoma

Trial Profile

Phase I Study of Intratumoral CV8102 in Patients With Advanced Melanoma, Squamous Cell Carcinoma of the Skin, Squamous Cell Carcinoma of the Head and Neck, or Adenoid Cystic Carcinoma

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 07 Nov 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CV 8102 (Primary) ; Programmed cell death-1 receptor antagonists
  • Indications Adenoid cystic carcinoma; Head and neck cancer; Malignant melanoma; Skin cancer; Solid tumours; Squamous cell cancer
  • Focus Adverse reactions
  • Sponsors CureVac
  • Most Recent Events

    • 03 Nov 2021 Status changed from recruiting to active, no longer recruiting.
    • 21 Sep 2021 Preliminary results from the completed dose escalation part presented at the 46th European Society for Medical Oncology Congress
    • 16 Aug 2021 According to a CureVac media release, the company expects to updates on the progress of this study at the European Society for Medical Oncology (ESMO) congress and the Society for Immunotherapy of Cancer (SITC) annual meeting later this year.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top